AST-120 in Hemodialysis Patients With Uremic Pruritus
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The prevalence of cutaneous pruritus among hemodialysis patients is about 50% to 80%. There
is only a handful of studies on the itchy skin of hemodialysis patients and the findings are
to be validated. Effective drugs to treat cutaneous pruritus are not available yet. Hence,
the purpose of the study is to eliminate the uremic toxins from the intestinal tract using
AST-120 as a treatment measure to improve the symptom of the hemodialysis patients' cutaneous
pruritus and discuss and assess its effectiveness. For this, the investigators will recruit
150 patients to validate the application potential of the AST-120 in the cutaneous pruritus
brought about by uremia.
Phase:
N/A
Details
Lead Sponsor:
Conmed Pharmaceutical & Bio-Medical Corporation
Collaborators:
Chang Gung Memorial Hospital Kaohsiung Medical University Taichung Veterans General Hospital Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Tri-Service General Hospital Tungs' Taichung Metroharbour Hospital